Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 02-07-2022 | Computed Tomography | Original Article

A first-in-human study of [⁶⁸Ga]Ga-CDI: a positron emitting radiopharmaceutical for imaging tumour cell death

Authors: Ivan Ho Shon, Thomas Hennessy, Jennifer Guille, Michael P. Gotsbacher, Angelina J. Lay, Bruce McBride, Rachel Codd, Philip J. Hogg

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2022

Abstract

Purpose

This study assesses human biodistribution, radiation dosimetry, safety and tumour uptake of cell death indicator labelled with ⁶⁸Ga ([⁶⁸Ga]Ga-CDI), a novel radiopharmaceutical that can image multiple forms of cell death.

Methods

Five participants with at least one extracranial site of solid malignancy > 2 cm and no active cancer treatment in the 8 weeks prior to the study were enrolled. Participants were administered 205 ± 4.1 MBq (range, 200–211 MBq) of [⁶⁸Ga]Ga-CDI and 8 serial PET scans acquired: the first commencing immediately and the last 3 h later. Participants were monitored for clinical, laboratory and electrocardiographic side effects and adverse events. Urine and blood radioactivity was measured. Spherical volumes of interest were drawn over tumour, blood pool and organs to determine biodistribution and calculate dosimetry. In one participant, tumour specimens were analysed for cell death using terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) staining.

Results

[⁶⁸Ga]Ga-CDI is safe and well-tolerated with no side effects or adverse events. [⁶⁸Ga]Ga-CDI is renally excreted, demonstrates low levels of physiologic uptake in the other organs and has excellent imaging characteristics. The mean effective dose was 2.17E − 02 ± 4.61E − 03 mSv/MBq. It images constitutive tumour cell death and correlates with tumour cell death on histology.

Conclusion

[⁶⁸Ga]Ga-CDI is a novel cell death imaging radiopharmaceutical that is safe, has low radiation dosimetry and excellent biodistribution and imaging characteristics. It has potential advantages over previously investigated radiopharmaceuticals for imaging of cell death and has progressed to a proof-of-concept trial.

Trial registration

ACTRN12621000641897 (28/5/2021, retrospectively registered)

Available only for authorised users

Schwartz LH, Bogaerts J, Ford R, Shankar L, Therasse P, Gwyther S, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer. 2009;45:261–7. https://doi.org/10.1016/j.ejca.2008.10.028.CrossRefPubMed

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-S150. https://doi.org/10.2967/jnumed.108.057307.CrossRefPubMed

Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nucl Med. 1999;40:184–91.PubMed

Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, et al. Increased uptake of the apoptosis-imaging agent ^99mTc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res. 2002;8:2766–74.PubMed

Haas RL, de Jong D, Valdes Olmos RA, Hoefnagel CA, van den Heuvel I, Zerp SF, et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys. 2004;59:782–7. https://doi.org/10.1016/j.ijrobp.2003.11.017/S0360301603023125[pii].CrossRefPubMed

Kemerink GJ, Liu X, Kieffer D, Ceyssens S, Mortelmans L, Verbruggen AM, et al. Safety, biodistribution, and dosimetry of ^99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application. J Nucl Med. 2003;44:947–52.PubMed

Belhocine TZ, Blankenberg FG, Kartachova MS, Stitt LW, Vanderheyden JL, Hoebers FJ, et al. (99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials. Eur J Nucl Med Mol Imaging. 2015;42:2083–97. https://doi.org/10.1007/s00259-015-3152-0.CrossRefPubMed

Challapalli A, Kenny LM, Hallett WA, Kozlowski K, Tomasi G, Gudi M, et al. ¹⁸F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry. J Nucl Med. 2013;54:1551–6. https://doi.org/10.2967/jnumed.112.118760.CrossRefPubMed

Dubash SR, Merchant S, Heinzmann K, Mauri F, Lavdas I, Inglese M, et al. Clinical translation of [¹⁸F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer. Eur J Nucl Med Mol Imaging. 2018;45:2285–99. https://doi.org/10.1007/s00259-018-4098-9.CrossRefPubMedPubMedCentral

10.

Park D, Don AS, Massamiri T, Karwa A, Warner B, MacDonald J, et al. Noninvasive imaging of cell death using an Hsp90 ligand. J Am Chem Soc. 2011;133:2832–5. https://doi.org/10.1021/ja110226y.CrossRefPubMedPubMedCentral

11.

Park D, Xie BW, Van Beek ER, Blankevoort V, Que I, Lowik CW, et al. Optical imaging of treatment-related tumor cell death using a heat shock protein-90 alkylator. Mol Pharm. 2013;10:3882–91. https://doi.org/10.1021/mp4003464.CrossRefPubMed

12.

Ho Shon I, Kumar D, Sathiakumar C, Berghofer P, Van K, Chicco A, et al. Biodistribution and imaging of an hsp90 ligand labelled with ¹¹¹In and ⁶⁷Ga for imaging of cell death. EJNMMI Res. 2020;10:4. https://doi.org/10.1186/s13550-020-0590-x.CrossRefPubMedPubMedCentral

13.

Ho Shon I, Gotsbacher MP, Guille J, Kumar D, Codd R, Hogg P. Preparation of a dithiol-reactive probe for PET imaging of cell death. Methods Mol Biol. 2019;1967:295–304. https://doi.org/10.1007/978-1-4939-9187-7_19.CrossRefPubMed

14.

Ho Shon I, Kumar D, Schreuder M, Guille J, Doan J, Sathikumar C, et al. Preclinical assessment of [⁶⁸Ga]Ga-cell death indicator (CDI): a novel hsp90 ligand for positron emission tomography of cell death. Curr Radiopharm. 2021;14:1-. https://doi.org/10.2174/1874471014666211122100646.CrossRef

15.

Ho Shon I, Reece C, Hennessy T, Horsfield M, McBride B. Influence of X-ray computed tomography (CT) exposure and reconstruction parameters on positron emission tomography (PET) quantitation. EJNMMI Phys. 2020;7:62. https://doi.org/10.1186/s40658-020-00331-w.CrossRefPubMedPubMedCentral

16.

Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294–310.CrossRef

17.

Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMed

18.

The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37:1–332. https://doi.org/10.1016/j.icrp.2007.10.003.

19.

Horsley L, Cummings J, Middleton M, Ward T, Backen A, Clamp A, et al. A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2013;72:1343–52. https://doi.org/10.1007/s00280-013-2320-9.CrossRefPubMed

20.

Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M. Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med. 2013;54:855–60. https://doi.org/10.2967/jnumed.112.114165.CrossRefPubMed

21.

Afshar-Oromieh A, Hetzheim H, Kubler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611–20. https://doi.org/10.1007/s00259-016-3419-0.CrossRefPubMed

22.

Pfob CH, Ziegler S, Graner FP, Kohner M, Schachoff S, Blechert B, et al. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:1962–70. https://doi.org/10.1007/s00259-016-3424-3.CrossRefPubMed

23.

Caruso R, Parisi A, Bonanno A, Paparo D, Quattrocchi E, Branca G, et al. Histologic coagulative tumour necrosis as a prognostic indicator of aggressiveness in renal, lung, thyroid and colorectal carcinomas: a brief review. Oncol Lett. 2012;3:16–8. https://doi.org/10.3892/ol.2011.420.CrossRefPubMed

24.

Gammon ST, Engel BJ, Gores GJ, Cressman E, Piwnica-Worms D, Millward SW. Mistiming death: modeling the time-domain variability of tumor apoptosis and implications for molecular imaging of cell death. Mol Imaging Biol. 2020;22:1310–23. https://doi.org/10.1007/s11307-020-01509-5.CrossRefPubMedPubMedCentral

25.

Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5:761–72. https://doi.org/10.1038/nrc1716.CrossRefPubMed

26.

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486–541. https://doi.org/10.1038/s41418-017-0012-4.CrossRefPubMedPubMedCentral

27.

Wiegman EM, Pruim J, Ubbels JF, Groen HJ, Langendijk JA, Widder J. (18)F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study. Eur J Nucl Med Mol Imaging. 2011;38:1059–63. https://doi.org/10.1007/s00259-010-1706-8.CrossRefPubMedPubMedCentral

28.

Tian F, Shen G, Deng Y, Diao W, Jia Z. The accuracy of (18)F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review. Eur Radiol. 2017;27:4786–96. https://doi.org/10.1007/s00330-017-4831-y.CrossRefPubMed

29.

Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol. 2018;19:965–74. https://doi.org/10.1016/S1470-2045(18)30201-8.CrossRefPubMed

Title: A first-in-human study of [68Ga]Ga-CDI: a positron emitting radiopharmaceutical for imaging tumour cell death
Authors: Ivan Ho Shon
Thomas Hennessy
Jennifer Guille
Michael P. Gotsbacher
Angelina J. Lay
Bruce McBride
Rachel Codd
Philip J. Hogg
Publication date: 02-07-2022
Publisher: Springer Berlin Heidelberg
Keywords: Computed Tomography
Computed Tomography
Positron Emission Tomography
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2022
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05880-z

At a glance: The STEP trials

Springer Medicine

A first-in-human study of [⁶⁸Ga]Ga-CDI: a positron emitting radiopharmaceutical for imaging tumour cell death

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 12/2022

Complementary value of metabolic and tau PET imaging in the diagnosis of corticobasal degeneration

Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria

Preclinical evaluation and pilot clinical study of [18F]AlF-NOTA-FAPI-04 for PET imaging of rheumatoid arthritis

Correction to: Visualizing γδ T cells by very late antigen-4-targeted positron emission tomography

Correction to: Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study

Predicting response of micrometastases with MIRDcell V3: proof of principle with 225Ac-DOTA encapsulating liposomes that produce different activity distributions in tumor spheroids